Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Lancet Infectious Diseases
Mar 2022 Volume 22 Number 3 p297-426, e66-e100
https://www.thelancet.com/journals/laninf/issue/current

 

Articles
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
Peter G Kremsner, et al. on behalf of the HERALD Study Group